Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de amivantamabe sozinho ou em adição a outros agentes de tratamento em participantes com câncer recorrente/metastático de cabeça e pescoço (OrigAMI-4)

2 de novembro de 2026 atualizado por: Janssen Research & Development, LLC

Um estudo aberto de fase 1b/2 de monoterapia com amivantamabe e amivantamabe em adição aos agentes terapêuticos padrão de tratamento em participantes com carcinoma espinocelular recorrente/metastático de cabeça e pescoço

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel. The safety and preliminary efficacy of amivantamab in addition to pembrolizumab will also be determined in perioperative (before and after surgery) setting in participants with resectable locally advanced head and neck squamous cell carcinoma (HNSCC).

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

287

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Essen, Alemanha, 45147
        • Recrutamento
        • Universitaetsklinikum Essen
      • Leipzig, Alemanha, 04103
        • Concluído
        • Universitaetsklinikum Leipzig
      • Stuttgart, Alemanha, 70174
        • Recrutamento
        • Klinikum der Landeshauptstadt Stuttgart
      • Beijing, China, 100142
        • Concluído
        • Beijing Cancer Hospital of Peking University
      • Cheng Du Shi, China, 610041
        • Recrutamento
        • West China School of Medicine/West China Hospital, Sichuan University
      • Linyi, China, 276002
        • Concluído
        • Linyi Cancer Hospital
      • Shanghai, China, 200120
        • Recrutamento
        • Shanghai East Hospital
      • Shanghai, China, 200032
        • Recrutamento
        • Fudan Cancer Hospital
      • Wuhan, China, 430022
        • Recrutamento
        • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital
      • Seoul, Coréia do Sul, 06351
        • Recrutamento
        • Samsung Medical Center
      • Seoul, Coréia do Sul, 03722
        • Recrutamento
        • Severance Hospital Yonsei University Health System
      • Barcelona, Espanha, 08908
        • Recrutamento
        • Inst. Cat. Doncologia-H Duran I Reynals
      • Barcelona, Espanha, 08035
        • Recrutamento
        • Hosp Univ Vall D Hebron
      • Madrid, Espanha, 28034
        • Recrutamento
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hosp. Univ. 12 de Octubre
    • California
      • La Jolla, California, Estados Unidos, 92093
        • Concluído
        • University of California at San Diego Moores Cancer Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • University of Colorado Denver Anschultz Medical Campus
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Recrutamento
        • Yale Cancer Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • The University of Chicago Medical Center (UCMC)
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Recrutamento
        • University of Maryland School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Recrutamento
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan Rogel Cancer Center
      • Detroit, Michigan, Estados Unidos, 48201 2013
        • Recrutamento
        • Karmanos Cancer Institute
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Washington University School Of Medicine
    • New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08901
        • Recrutamento
        • Rutgers Cancer Institute of New Jersey
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Recrutamento
        • University of North Carolina at Chapel Hill
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Recrutamento
        • Cleveland Clinic
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Recrutamento
        • University of Utah Huntsman Cancer Institute
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22903
        • Recrutamento
        • University of Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • Virginia Cancer Specialists
      • Avignon, França, 84918
        • Recrutamento
        • Institut Sainte Catherine
      • Lille, França, 59000
        • Recrutamento
        • Centre Oscar Lambret
      • Nantes, França, 44000
        • Recrutamento
        • CHU Nantes
      • Paris, França, 75248
        • Recrutamento
        • Institut Curie
      • Villejuif, França, 94805
        • Recrutamento
        • Gustave Roussy
      • Nagoya, Japão, 464-8681
        • Recrutamento
        • Aichi Cancer Center
      • Tokyo, Japão, 160-0023
        • Recrutamento
        • Tokyo Medical University Hospital
      • Kuala Lumpur, Malásia, 59100
        • Recrutamento
        • University Malaya Medical Centre
      • Kuala Lumpur, Malásia, 59100
        • Recrutamento
        • Pantai Hospital Kuala Lumpur
      • Gdansk, Polônia, 80 214
        • Recrutamento
        • Uniwersyteckie Centrum Kliniczne
      • Gliwice, Polônia, 44-102
        • Recrutamento
        • Centrum Onkologii Instytut im M Sklodowskiej Curie Oddzial w Gliwicach
      • Warsaw, Polônia, 02 781
        • Recrutamento
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Cambridge, Reino Unido, CB2 0QQ
        • Recrutamento
        • Addenbrooke's Hospital
      • Guildford, Reino Unido, GU2 7XX
        • Recrutamento
        • The Royal Surrey County Hospital NHS Foundation Trust
      • London, Reino Unido, SW3 6JJ
        • Recrutamento
        • Royal Marsden Hospital
      • London, Reino Unido, W1T 7HA
        • Recrutamento
        • University College London Hospitals
      • London, Reino Unido, SM2 5PT
        • Recrutamento
        • Royal Marsden Hospital (Sutton)
      • London, Reino Unido, W12 0HS
        • Concluído
        • Imperial College London and Imperial College Healthcare NHS Trust
      • Manchester, Reino Unido, M20 4BX
        • Recrutamento
        • The Christie Nhs Foundation Trust
      • Changhua, Taiwan, 500
        • Recrutamento
        • Changhua Christian Hospital
      • Kaohsiung City, Taiwan, 833
        • Recrutamento
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwan, 100
        • Recrutamento
        • National Taiwan University Hospital
      • Taipei, Taiwan, 112
        • Recrutamento
        • Taipei Veterans General Hospital
      • Taoyuan, Taiwan, 33382
        • Recrutamento
        • Linkou Chang Gung Memorial Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Cohorts 1 to 5: Have histologically or cytologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that is considered incurable by local therapies or for Cohort 6: have histologically or cytologically confirmed locally advanced (L/A) HNSCC that is considered curable by surgery Acceptable prior lines of therapy will be determined according to specific cohort 1, 2, 3A and 3B: (a) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (b) Any known p16 status of tumor must be negative (Note: All participants with an oropharyngeal tumor must have results of p16 status, per local testing); (c) Participants must provide local testing results of programmed cell death ligand 1 (PD-L1) status, if available; Cohort 4: (d) Patients must have primary tumor location in oropharynx. Unknown primary tumors are not included (e) Primary tumor must be HPV-positive, confirmed by positive p16 test or high-risk human papillomavirus (HPV) in-situ hybridization (ISH) in tissue (current or archival) (f) Participants must provide local testing results of PD-L1 status, if available; Cohort 5 (g) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (h) HPV status must be known (either positive or negative) for patients with primary tumor location in oropharynx with p16 test or high-risk HPV ISH in tissue; (i) Participants must provide local testing results of PD-L1 status; Cohort 6: (j) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (k) Any known p16 status of tumor must be negative Note: All participants with an oropharyngeal tumor must have results of p16 status, per local testing Participants must provide local testing results of PD-L1 status (l) Participants must have Stage III or IVa disease (American Joint Committee on Cancer Staging Manual, 8th edition). Participants must have resectable disease
  • Participants in Cohorts 1, 2, 3B, 4 and 5 must have measurable disease according to RECIST version 1.1. Participants in Cohort 3A and Cohort 6 must have evaluable disease (defined as having at least 1 non-target lesion according to RECIST version 1.1.
  • Cohorts 1, 2, 3A, 3B, 4, and 5 only: Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less prior to the first dose of study treatment (except for alopecia or post-radiation skin changes [any grade], Grade less than or equal to [<=]2 peripheral neuropathy and Grade <=2 hypothyroidism stable on hormone replacement)
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participant must have adequate organ and bone marrow function as follows, without history of red blood cell transfusion, platelet transfusion, or use of granulocyte colony-stimulating factor within 7 days prior to the date of the laboratory test.

Participants should have: a) Hemoglobin >=9 grams per deciliter (g/dL); b) Neutrophils >=1.5 x 10^3/mcg; c) Platelets >=100 x 10^3/mcg

Exclusion Criteria:

  • Uncontrolled illness including any medical history or current (non-infectious) interstitial lung disease (ILD)/ pneumonitis/ pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
  • Participant with untreated brain metastases leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation
  • Participant with a history of clinically significant cardiovascular disease
  • Received prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study treatment. The maximum required washout is 28 days
  • Received radiotherapy for palliative purposes within 7 days of the first administration of study treatment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cohort 1: Amivantamab Monotherapy (Dose Expansion)

Participants will receive subcutaneous injection of amivantamab monotherapy 1600 milligrams (mg) (2240 mg, if body weight >=80 kilograms [kg]) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) once every week (q1w) for the remainder of Cycle 1 (Days 8 and 15), and every 3 weeks (q3w) from Cycle 2 onwards.

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372
Experimental: Cohort 2: Amivantamab + Pembrolizumab (Dose Expansion Including Safety Run-in)

Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous (IV) injection of pembrolizumab 200 mg q3w (on Day 1 of each 21-day cycle).

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372

Pembrolizumab will be administered intravenously.

Outros nomes:
  • KEYTRUDA
Experimental: Cohort 3A (Dose Confirmation): Amivantamab + Paclitaxel

Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous injection of paclitaxel 175 mg/m^2 q3w (on Day 1 of each 21-day cycle) in dose confirmation Cohort 3A. The recommended Phase 2 combination dose (RP2CD) of amivantamab will be determined in conjunction with study evaluation team (SET) in this dose confirmation Cohort 3A.

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372

Paclitaxel will be administered intravenously.

Outros nomes:
  • TAXOL
Experimental: Cohort 3B (Dose Expansion): Amivantamab + Paclitaxel

Participants will receive subcutaneous injection of amivantamab at the determined RP2CD in addition to intravenous injection of paclitaxel 175 mg/m^2 q3w (on Day 1 of each 21-day cycle) as confirmed by SET in Cohort 3A.

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372

Paclitaxel will be administered intravenously.

Outros nomes:
  • TAXOL
Experimental: Cohort 4: Amivantamab Monotherapy

Participants will receive subcutaneous injection of amivantamab monotherapy 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards.

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372
Experimental: Cohort 5: Pembrolizumab + Amivantamab + Carboplatin (Dose Expansion)

Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards in addition to intravenous injection of pembrolizumab 200 mg on Day 1 of each cycle, and carboplatin (area under the concentration-time curve [AUC] 5 milligram per milliliter [mg/ml]*min) q3w on Day 1 of Cycles 1-6.

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372

Pembrolizumab will be administered intravenously.

Outros nomes:
  • KEYTRUDA

Carboplatin will be administered intravenously.

Outros nomes:
  • PARAPLATIN
Experimental: Cohort 6: Amivantamab + Pembrolizumab

Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2, along with intravenous injection of pembrolizumab 200 mg q3w (on Day 1 of each 21-day cycle) (Neoadjuvant Phase). In the adjuvant phase, pembrolizumab IV (200 mg) will be administered q3w from Adjuvant Cycle 1 Day 1 to Adjuvant Cycle 15 Day 1 and amivantamab SC 2,400 mg (3,360 mg for >80 kg) will be administered q3w from Adjuvant Cycle 4 Day 1 to Adjuvant Cycle 15 Day 1.

Amivantamab will be administered subcutaneously.

Outros nomes:
  • JNJ-61186372

Pembrolizumab will be administered intravenously.

Outros nomes:
  • KEYTRUDA

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Cohorts 1, 2, 3B, 4 and 5: Objective Response Rate
Prazo: 2 years and 2 months

ORR is defined as the proportion of participants who achieve either a partial response (PR) or complete response (CR), as defined by investigator assessment using Response Criteria in Solid Tumors (RECIST) version 1.1.

2 years and 2 months
Cohort 3A: Number of Participants With Dose-limiting Toxicities (DLT)
Prazo: Up to 21 days

Number of participants with DLTs will be reported. A DLT is defined as any of the following: treatment delay of greater than (>) 28 days due to unresolved toxicity, non-hematologic toxicity of Grade 3 or higher, hematologic toxicity of Grade 4 neutropenia persisting for >7 days or Grade 3 or higher thrombocytopenia with clinically significant bleeding or neutropenic fever of any grade, and liver enzyme elevation.

Up to 21 days
Cohort 3A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity
Prazo: 2 years and 1 month

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

2 years and 1 month
Cohort 6: Major Pathologic Response (MPR)
Prazo: 2 years and 2 months

The participants who achieve MPR at the time of surgery.

2 years and 2 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Cohorts 1, 2, 3B, 4 and 5: Duration of Response (DoR)
Prazo: 2 years and 2 months

DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR.

2 years and 2 months
Cohorts 1, 2, 3B, 4 and 5: Clinical Benefit Rate (CBR)
Prazo: 2 years and 2 months

CBR is defined as the percentage of participants achieving a confirmed complete or partial response, or durable stable disease (the second disease assessment) as defined by RECIST version 1.1.

2 years and 2 months
Cohorts 1, 2, 3B, 4 and 5: Progression-free Survival (PFS)
Prazo: 2 years and 2 months

PFS is defined as the time from the first administration of study treatment until the date of objective disease progression or death, whichever comes first, based on investigator assessment using RECIST version 1.1.

2 years and 2 months
Cohorts 1, 2, 3B, 4, 5 and 6: Overall Survival (OS)
Prazo: 2 years and 2 months

OS is defined as the time from the first administration of study treatment until the date of death due to any cause.

2 years and 2 months
Cohorts 1, 2, 3B, 4, 5 and 6: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity
Prazo: 2 years and 1 month

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events.

2 years and 1 month
Cohort 1 and 4: Maximum Observed Serum Concentration (Cmax) of Amivantamab
Prazo: Predose up to 168 hours post dose on Day 1

Cmax is defined as maximum observed serum concentration of amivantamab.

Predose up to 168 hours post dose on Day 1
Cohort 1 and 4: Time to Maximum Observed Serum Concentration (Tmax) of Amivantamab
Prazo: Predose up to 168 hours post dose on Day 1

Tmax is defined as time to maximum observed serum concentration of amivantamab.

Predose up to 168 hours post dose on Day 1
Cohort 1 and 4: Area Under the Serum Concentration Curve Verses Time Curve From Time t1 to t2 (AUC[t1-t2]) of Amivantamab
Prazo: Predose up to 168 hours post dose on Day 1

AUC(t1-t2) is defined as area under the serum concentration versus time curve from time t1 to time t2 of amivantamab.

Predose up to 168 hours post dose on Day 1
Cohort 1 and 4: Area Under the Curve From Time Zero to tau (AUC[0-tau]) of Amivantamab
Prazo: Predose up to 168 hours post dose on Day 1

AUC(0-tau) is defined as area under the curve from time 0 to tau hours of amivantamab.

Predose up to 168 hours post dose on Day 1
Cohort 1 and 4: Trough Serum Concentration (Ctrough) of Amivantamab
Prazo: Predose up to 168 hours post dose on Day 1

Ctrough is defined as the serum concentration of amivantamab.

Predose up to 168 hours post dose on Day 1
Cohort 1 and 4: Accumulation Ratio (R) of Amivantamab
Prazo: Predose up to 168 hours post dose on Day 1

Accumulation ratio (R) is calculated as area under the serum concentration-time curve from time zero to 168 hours (AUC[0-168]) value at Cycle 2 Day 1 dose divided by AUC(0-168) value after Cycle 1 Day 1 amivantamab dose.

Predose up to 168 hours post dose on Day 1
Cohort 6: Event-Free Survival (EFS)
Prazo: 2 years and 2 months

EFS is defined as the time from the first administration of study treatment until the date of radiographic disease progression, local or distant progression or recurrence as assessed with imaging or biopsy as indicated, or death due to any cause.

2 years and 2 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

22 de abril de 2024

Conclusão Primária (Estimado)

27 de dezembro de 2032

Conclusão do estudo (Estimado)

28 de julho de 2033

Datas de inscrição no estudo

Enviado pela primeira vez

23 de abril de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de abril de 2024

Primeira postagem (Real)

25 de abril de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 61186372HNC2002
  • 61186372HNC2002 (Outro identificador: Janssen Research & Development, LLC)
  • 2023-508418-40-00 (Identificador de registro: EUCT number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .